MSMutita Siriruchatanon

Mutita Siriruchatanon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mutita Siriruchatanon has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Miriam P. Rosin

    Cancer Control Research British Columbia Cancer Research Institute Vancouver Canada

    2 shared publications
  • Stella K. Kang

    Department of Population Health New York University Grossman School of Medicine New York New York USA

    2 shared publications
  • Stella K. Kang

    Department of Radiology, Columbia University Irving Medical Center, New York, NY

    2 shared publications
  • A. Ross Kerr

    Department of Oral and Maxillofacial Pathology, Radiology, and Medicine New York University College of Dentistry New York New York USA

    1 shared publication
  • Aisha Tene Langford

    Department of Family Medicine and Public Health Sciences, Wayne State University, 6135 Woodward Ave, Detroit, MI, 48111, United States, 1 3135775644

    1 shared publication
  • Alexander R. Kerr

    Department of Oral and Maxillofacial Pathology, Radiology, and Medicine, New York University College of Dentistry, New York, NY, USA

    1 shared publication

Latest Publications

  • Radiology Workflow Assistance With Artificial Intelligence: Establishing the Link to Outcomes

    by Zehui Gu, Siddhant Dogra, Mutita Siriruchatanon, Jerard Kneifati-Hayek, Stella K. Kang


  • Open Access

    Clinical Features Associated With Malignant Transformation of Low‐Grade Dysplasia

    by Denise M. Laronde, Matt Berkowitz, A. Ross Kerr, Erinn M. Hade, Mutita Siriruchatanon, Miriam P. Rosin, Stella K. Kang

    Background: Inferring risk for malignant transformation ( MT ) in patients with lesions diagnosed as mild or moderate oral epithelial dysplasia (low‐grade OED ) remains challenging. We developed two models assessing the risk of progression to high‐grade OED (severe dysplasia or carcinoma in situ) or OSCC in patients with low‐grade OED lesions. Methods: We included demographic, risk habit and clinical data from participants with low‐grade OED lesions enrolled in the BC Oral Cancer Prevention Program's Oral Cancer Prediction Longitudinal study. Cox proportional hazard models were fit to estimate the effects of anatomic site and toluidine blue findings and adjusted for confounders, as both are associated with MT in the literature but without a North American‐specific cohort analysis. Our primary model included both variables of interest. A secondary model included only anatomic site since toluidine blue is not in widespread use. Results: Five hundred and thirty‐four participants with 605 lesions met final inclusion criteria, with 339 mild and 266 moderate OED at baseline. In the primary model, lesions at a high‐risk anatomic site or with positive toluidine blue staining were associated with a 2.6 and 2.4‐fold increased risk of progression, respectively. In the second model that did not incorporate toluidine blue, high‐risk anatomic site remained a highly associated risk factor (2.7‐fold increased risk of progression). Conclusion: Lesion anatomic site is associated with higher risk of MT for the general practitioner, while a specialist with access to toluidine blue results can assume additional risk associated with positive staining. These models may inform decisions for surveillance and intervention for OED .


  • Open Access

    Simulation Modeling of Oral Cancer Development with Risk Stratification: How Potential Screening Programs Can Be Evaluated

    by Mutita Siriruchatanon, Emily R. Brooks, Alexander R. Kerr, Denise M. Laronde, Miriam P. Rosin, Stella K. Kang

    Background. A barrier to early-stage oral cavity cancer detection is the lack of a defined population and screening regimen satisfying risk–benefit considerations. Methods. We constructed a microsimulation model, Simulation of Cancers of the Oral cavity and Risk Exposures (SCORE), that incorporates risk profiles defined by smoking and alcohol exposure. SCORE simulates the development and progression of oral potentially malignant disorders (OPMD) representing benign, dysplastic, or malignant lesions in the US population starting at age 40 y. OPMD high-risk characteristics of malignant transformation informed a biopsy decision rule. SCORE was calibrated to national cancer registry data. We compared life expectancy in those aged 40 to 60 y with OPMDs, cancer incidence, and cancer-specific deaths across screening strategies with and without the biopsy decision rule, assuming screening every 3 y starting at age 50 y. Results. In US men, all screening strategies reduced cancer incidence and cancer-specific mortality by at least 26% and 20% compared with no screening. Whether with or without a biopsy decision rule, life expectancy among those aged 40 to 60 y with OPMDs was 36.37 ± 0.01 life-years, a gain of 0.03 life-years. However, the use of the biopsy rule improved diagnostic efficiency with 8 biopsies per treatable diagnosis. Screening with or without the biopsy decision rule in high-risk men demonstrated comparable benefit, reducing cancer-specific deaths by 27% and incidence by 20% compared with no screening. Meanwhile, in the non-high-risk subpopulation, applying the biopsy rule avoided the harms of excess procedures, reducing lifetime biopsies by 38% versus biopsy of all OPMDs while preserving reductions in cancer burden. Conclusions. SCORE enables virtual trials of various screening regimens and target populations. Given the time and cost of clinical trials, SCORE may facilitate the evaluation of new technologies and clinical recommendations. Highlights: A new oral cancer simulation model with risk factors including degrees of smoking and alcohol exposure, oral lesion features, and sex incorporates more accurate and precise representation of patient risk categories. We evaluated screening strategies for oral potentially malignant disorders with or without risk-stratified biopsy referral in both the general population and subpopulations defined by degrees of smoking and alcohol exposure. Men with a high degree of both smoking and alcohol exposure exhibited a significant reduction in cancer-specific deaths and cancer incidence from screening programs for oral potentially malignant disorders. Screening with risk-stratified biopsy, using a surgical treatment threshold of moderate dysplasia or worse, yielded the greatest efficiency in term of biopsies needed to detect 1 treatable case.

  • Open Access

    An Evaluation of a Web-Based Decision Aid for Treatment Planning of Small Kidney Tumors: Pilot Randomized Controlled Trial

    by Justin Fogarty, Mutita Siriruchatanon, Danil Makarov, Aisha Langford, Stella Kang

    Background: Surgery is the most common treatment for localized small kidney masses (SKMs) up to 4 cm, despite a lack of evidence for improved overall survival. Nonsurgical management options are gaining recognition, as evidence supports the indolence of most SKMs. Decision aids (DAs) have been shown to improve patient comprehension of the trade-offs of treatment options and overall decision quality, and may improve consideration of all major options according to individual health priorities and preferences. Objective: This pilot randomized controlled trial (RCT) primarily aims to evaluate the impact of a new web-based DA on treatment decisions for patients with SKM; that is, selection of surgical versus nonsurgical treatment options. Secondary objectives include an assessment of decision-making outcomes: decisional conflict, decision satisfaction, and an understanding of individual preferences for treatment that incorporate the trade-offs associated with surgical versus nonsurgical interventions. Methods: Three phases comprise the construction and evaluation of a new web-based DA on SKM treatment. In phase 1, this DA was developed in print format through a multidisciplinary design committee incorporating patient focus groups. Phase 2 was an observational study on patient knowledge and decision-making measures after randomization to receive the printed DA or institutional educational materials, which identified further educational needs applied to a web-based DA. Phase 3 will preliminarily evaluate the web-based DA: in a pilot RCT, 50 adults diagnosed with SKMs will receive the web-based DA or an existing web-based institutional website at urology clinics at a large academic medical center. The web-based DA applies risk communication and information about diagnosis and treatment options, elicits preferences regarding treatment options, and provides a set of options to consider with their doctor based on a decision-analytic model of benefits/harm analysis that accounts for comorbidity, age group, and tumor features. Questionnaires and treatment decision data will be gathered before and after viewing the educational material. Results: This phase will consist of a pilot RCT from August 2022 to January 2023 to establish feasibility and preliminarily evaluate decision outcomes. Previous study phases from 2018 to 2020 supported the feasibility of providing the printed DA in urology clinics before clinical consultation and demonstrated increased patient knowledge about the diagnosis and treatment options and greater likelihood of favoring nonsurgical treatment just before consultation. This study was funded by the National Cancer Institute. Recruitment will begin in August 2022. Conclusions: A web-based DA has been designed to address educational needs for patients making treatment decisions for SKM, accounting for comorbidities and treatment-related benefits and risks. Outcomes from the pilot trial will evaluate the potential of a web-based DA in personalizing treatment decisions and in helping patients weigh attributes of surgical versus nonsurgical treatment options for their SKMs. Trial Registration: ClinicalTrials.gov NCT05387863; https://clinicaltrials.gov/ct2/show/NCT05387863 International Registered Report Identifier (IRRID): PRR1-10.2196/41451

  • Open Access

    Personalized Treatment Selection Algorithm in Chronic Depression: A Comparison of Model-Based and Model-Free Approaches

    by Mutita Siriruchatanon, Shan Liu

    Chronic depression is one of the leading causes for disability and severely impacts quality of life in US adults. As the disease can progress uniquely from patient-to-patient, clinical guidelines should not be one-size-fits-all for every patient. This heterogeneity highlights a need for the development of treatment selection algorithms that leverage person-level data and account for uncertainty in patient treatment response. We formulate the treatment selection problem for patients with chronic depression as a Markov Decision Process with the objective of finding the optimal treatment policy. Patients are categorized by their disease progression patterns and are assumed to have a latent treatment response type, i.e., responding the best to one of the available treatments. To create personalized treatment plans, we propose 1) a model-based approach that requires foreknowledge of the natural history disease model, 2) a model-free approach – Fitted-Q Iteration that relies only on patient observations, and they are investigated as alternatives to 3) a rule-based policy based on expert experience and clinical guidelines. Using simulated patient trajectories, we evaluate their policy performance under metrics such as health outcomes and accuracy in identifying a patient’s latent treatment response type. Our results show that the model-based algorithm provides the best policy with the highest health outcomes and accuracy in identifying the most effective treatment to each patient. It is also robust to changes in health utility, treatment disutility and probability of treatment discontinuation.